CellWell record HH-408643
Impact of Time of Administration, Fasting, and a Low-Carbohydrate Diet on Alpelisib-Associated Hyperglycemia and Efficacy: A Pilot Randomized Controlled Phase IIb Trial
Eduard Vrdoljak; Marija Pancirov; Josipa Flam; Dora Čerina Pavlinović; Matea Jakas Vučić; Marica Barać; Natalija Dedić Plavetić; Paula Podolski; Mladen Krnić; Žarko Bajić
2026
In plain language
In a pilot trial of 42 breast cancer patients, evening alpelisib after fasting with low-carbohydrate guidance showed a nonsignificant trend toward fewer severe hyperglycemia events than morning dosing, with no loss of efficacy.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-408643
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.